On June 24, Giant Biogene rose 5.45% in regular trading, trading at 26.22 HKD/share, with turnover of approximately 73.63 million HKD. The stock outperformed its Personal Products peers, all of which declined during the session.
On the news front, the company's wholly-owned subsidiary Shaanxi Giant Biogene Technology Co., Ltd. recently obtained the China Medical Device Registration Certificate for its crosslinked recombinant collagen implant. The product is the world's first crosslinked recombinant Type III full-length collagen filler approved for neck wrinkle indications, comprising 1,068 amino acids that fully preserve the natural functional domains of collagen. It utilizes a physical crosslinking process with no chemical crosslinker residue risk, forming a stable three-dimensional gel network for dermal injection to correct moderate-to-severe neck wrinkles.
Multiple brokerages have reaffirmed positive outlooks. CICC maintained its Outperform rating with a target price of 40 HKD, noting the product's differentiated advantage. Orient Securities maintained a Buy rating with a target price of 43.07 HKD, highlighting that the approval will help the company build a full-category matrix spanning Class III and Class II medical devices alongside skincare products, covering medical aesthetics, lifestyle beauty, and home beauty scenarios.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments